Presentation is loading. Please wait.

Presentation is loading. Please wait.

Twenty-year comparison of tissue and mechanical valve replacement

Published byLaurits Lindegaard Modified over 5 years ago

Similar presentations

Presentation on theme: "Twenty-year comparison of tissue and mechanical valve replacement"— Presentation transcript:

1 Twenty-year comparison of tissue and mechanical valve replacement
Steven S. Khan, MD, FACCa, Alfredo Trento, MDb, Michele DeRobertis, RNb, Robert M. Kass, MDb, Meenu Sandhu, MSc, Lawrence S.C. Czer, MDa, Carlos Blanche, MDb, Sharo Raissi, MDb, Gregory P. Fontana, MDb, Wen Cheng, MDb, Aurelio Chaux, MDc, Jack M. Matloff, MD*  The Journal of Thoracic and Cardiovascular Surgery  Volume 122, Issue 2, Pages (August 2001) DOI: /mtc Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

2 Fig. 1 Freedom from embolism for tissue and St Jude Medical valves. A, Aortic valve embolism data; B, mitral valve embolism data. The P value compares tissue and mechanical valve embolism rates. The numbers below the figure are the numbers of patients at risk at the beginning of each time period. NS , Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

3 Fig. 2 Freedom from hemorrhage comparing tissue and St Jude Medical valves stratified by valve position. A, Aortic hemorrhage rates; B, mitral hemorrhage rates. NS , Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

4 Fig. 3 Actuarial and actual freedom from reoperation for tissue and mechanical valves categorized by age. The P values refer to the comparison of the actuarial tissue and mechanical data. A, Aortic tissue valve recipients; B, mitral tissue valve recipients. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

5 Fig. 4 Annual risk (hazard) of undergoing valve reoperation. A, Aortic tissue valve recipients; B, mitral tissue valve recipients. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

6 Fig. 5 Survival stratified by patient age. A, Aortic tissue and St Jude Medical valve recipients; B, mitral tissue and St Jude Medical valve recipients. NS , Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

7 Fig. 6 Freedom from all valve complications, including valve thrombosis, embolism, hemorrhage, perivalvular leak, structural failure, endocarditis, pannus formation, annular erosion, reoperation, valve-related death, death within 30 days of reoperation, valve failure, and hemolysis. A, Aortic valve recipients; B, mitral valve recipients. Two statistical tests are shown; the Wilcoxon-Breslow test gives greater weight to early events, and the Mantel-Cox test weights early and late events equally. NS , Not significant. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2001 American Association for Thoracic Surgery Terms and Conditions

Download ppt "Twenty-year comparison of tissue and mechanical valve replacement"

Similar presentations

Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,

Resection of ascending aortic aneurysm without use of an interposition aortic graft John S. Ikonomidis, MD, PhD, FRCS(C), Abe DeAnda, MD, D.Craig Miller,
Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,

Tubular heart valves: A new tissue prosthesis design—Preclinical evaluation of the 3F aortic bioprosthesis James L. Cox, MD, Niv Ad, MD, Keith Myers, BS,
W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P
Volume 91, Issue 4, Pages (April 1987)

Volume 91, Issue 4, Pages (April 1987)
Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.
Twenty-Five Year Experience With the St

Twenty-Five Year Experience With the St
Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years  John B. Chambers, MD, FRCP,

Clinical event rates with the On-X bileaflet mechanical heart valve: A multicenter experience with follow-up to 12 years  John B. Chambers, MD, FRCP,
Clinical experience with the carbomedics valve: Early results with a new bileaflet mechanical prosthesis  J.Francisco Nistal, MD, Aquilino Hurlé, MD,

Clinical experience with the carbomedics valve: Early results with a new bileaflet mechanical prosthesis  J.Francisco Nistal, MD, Aquilino Hurlé, MD,
Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study  Vincent Chan,
Sergey Leontyev, MD, Michael A

Sergey Leontyev, MD, Michael A
In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.

In which patients is transcatheter aortic valve replacement potentially better indicated than surgery for redo aortic valve disease? Long-term results.
Danny Ramzy, MD, PhD, Alfredo Trento, MD, Wen Cheng, MD, Michele A

Danny Ramzy, MD, PhD, Alfredo Trento, MD, Wen Cheng, MD, Michele A
Risk Factors Associated With Reoperation and Mortality in 252 Patients After Aortic Valve Replacement for Congenitally Bicuspid Aortic Valve Disease 

Risk Factors Associated With Reoperation and Mortality in 252 Patients After Aortic Valve Replacement for Congenitally Bicuspid Aortic Valve Disease 
Prospective randomized comparison of CarboMedics and St

Prospective randomized comparison of CarboMedics and St
Bigger valve size is not always better

Bigger valve size is not always better
When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 

When is the Ross operation a good option to treat aortic valve disease?  Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc 
Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age  Torsten Christ,
W. R. Eric Jamieson, MD, Guy J. Fradet, MD, James G

W. R. Eric Jamieson, MD, Guy J. Fradet, MD, James G
Aortic valve replacement with the biocor PSB stentless xenograft

Aortic valve replacement with the biocor PSB stentless xenograft
Early degeneration of the St Jude Medical Trifecta bioprosthetic aortic valve: A problem of the leaflets or of the stent?  Giuseppe Santarpino, MD, Steffen.

Early degeneration of the St Jude Medical Trifecta bioprosthetic aortic valve: A problem of the leaflets or of the stent?  Giuseppe Santarpino, MD, Steffen.

Similar presentations

Ads by Google